Reviva Pharmaceuticals Holdings (RVPH) Interest & Investment Income (2018 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Interest & Investment Income of $89354.0 for Q1 2026, down 37.65% sequentially from $143309.0 in Q4 2025, and up 3.77% YoY from $86111.0 in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Interest & Investment Income (2018 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Interest & Investment Income for 8 years, with the latest figure at $89354.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 3.77% year-over-year to $89354.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $314613.0 (up 14.66% YoY) and the FY2025 annual result came in at $311370.0, down 13.84% from the prior year.
- Interest & Investment Income declined to $89354.0 in Q1 2026 per RVPH's latest filing, from $143309.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $173098.0 in Q1 2024 and troughed at $1735.0 in Q1 2022.
- A 5-year average of $79018.1 and a median of $86111.0 in 2025 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income jumped 9816.64% in 2022, then tumbled 73.92% in 2025.
- Over 5 years, Interest & Investment Income stood at $114092.0 in 2022, then plunged by 50.43% to $56559.0 in 2023, then dropped by 16.17% to $47413.0 in 2024, then surged by 202.26% to $143309.0 in 2025, then tumbled by 37.65% to $89354.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $89354.0, $143309.0, and $59103.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | 176,319.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 176,319.00 |
| Mar 31, 2026 | 89,354.00 |
| Dec 31, 2025 | 143,309.00 |
| Sep 30, 2025 | 59,103.00 |
| Jun 30, 2025 | 22,847.00 |
| Mar 31, 2025 | 86,111.00 |
| Dec 31, 2024 | 47,413.00 |
| Sep 30, 2024 | 53,248.00 |
| Jun 30, 2024 | 87,610.00 |
| Mar 31, 2024 | 173,098.00 |
| Dec 31, 2023 | 56,559.00 |
| Sep 30, 2023 | 91,763.00 |
| Jun 30, 2023 | 103,080.00 |
| Mar 31, 2023 | 147,011.00 |
| Dec 31, 2022 | 114,092.00 |
| Sep 30, 2022 | 53,150.00 |
| Jun 30, 2022 | 13,825.00 |
| Mar 31, 2022 | 1,735.00 |
| Dec 13, 2021 | 1,534.00 |
| Sep 30, 2021 | -547.00 |